Advertisement

Picture Campus Berlin-Buch GmbH CBB Location of Future Innovation 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in Austria, Germany and Switzerland or involving organisations from these countries.

Total search results: 4947 | Ordered by Date (descending)
next pagenext page 1 2 3 ... 5 6 7 ... 48 49 50  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
Freenome–HBM: investment, 202112 financing round Series D totalling $300m incl new + co-investor HBM Healthcare Investments 2021-12-07
Freenome–Novartis: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Novartis 2021-12-07
Freenome–Roche: investment, 202112 financing round Series D totalling $300m incl existing + co-investor Roche Venture Fund 2021-12-07
Freenome–SEVERAL: investment, 202112 financing round Series D $300m co-led by Perceptive Advisors + RA Capital Management 2021-12-07
Freenome–Siemens: breast cancer diagnostics, 202112– collab research using imaging + multi-omics to identify markers for early detection 2021-12-07
Odyssey Therapeutics–HBM: investment, 202112 financing round Series A totalling $218m incl co-investor HBM Healthcare Investments 2021-12-07
Odyssey Therapeutics–SEVERAL: investment, 202112 financing round Series A $218m led by OrbiMed Advisors + co-led by SR One 2021-12-07
Quay Pharmaceuticals–SGS: investment, 202112 acquisition of Quay Pharma by SGS 2021-12-07
Roche–Recursion Pharmaceuticals: AI-based drug discovery, 202112– strategic collab $150m upfront up to 40 programs to be selected by Roche+Genentech 2021-12-07
Novartis–UCB: Parkinson drugs, 202112– collab up to $1.5b with $150m upfront ww developm + commercialisation of UCB0599 + option for UCB7853 2021-12-02
Origimm Biotechnology–Sanofi: investment, 202112– acquisition by Sanofi SIGNED 2021-12-01
SciRhom–High-Tech Gründerfonds: investment, 202111 existent HTGF is existing seed investor 2021-11-30
SciRhom–SEVERAL: investment, 202111 seed financing round extension €8m bringing total funding to €16m 2021-11-30
Dermagnostix–SEVERAL: investment, 202111 7-digit € seed financing round 2021-11-26
Lindera–SEVERAL: investment, 202111 financing round Series A €6m incl new investor family office zwei.7 2021-11-25
Lindera–Wulf Group: investment, 202111 financing round Series A totalling €6m incl new investor family office zwei.7 2021-11-25
Relief Therapeutics–BioXcel: AI-based drug discovery, 202111– strategic collab €na using AlphaMeld platform of InveniAI for drug discovery 2021-11-24
Innerspace–Austria (govt): investment, 202111 2nd seed financing round totalling 7-digit € incl new investor aws Gründerfonds 2021-11-23
Innerspace–High-Tech Gründerfonds: investment, 202111 2nd seed financing round totalling 7-digit € incl existing investor HTGF 2021-11-23
Innerspace–MAD Ventures: investment, 202111 2nd seed financing round totalling 7-digit € incl existing investor MAD Ventures GmbH 2021-11-23
Innerspace–SEVERAL: investment, 202111 2nd seed financing round 7-digit € with MAD Ventures + HTGF + aws Gründerfonds 2021-11-23
LoQus23 Therapeutics–Novartis: investment, 202111 extended seed financing round totalling £7m incl new investor NVF 2021-11-23
LoQus23 Therapeutics–SEVERAL: investment, 202111 extended seed financing round £7m from founding investor DDF + new investor NVF 2021-11-23
Inositec–Vifor Pharma: investment, 202211 acquisition 100% for CHF20m upfront + low triple digit million milestones 2021-11-22
Sanifit–Vifor Pharma: investment, 202211 acquisition 100% for €205m upfront + €170m precommercial milestones + rgoressive commercial milestones 2021-11-22
Molecubes–Bruker: investment, 202111 acquisition €na by Bruker 2021-11-19
Axel Semrau–Trajan: investment, 202111 acquisition €19.85m by Trajan Group 2021-11-18
Bruker–Bico: MS-based single cell proteomics, 202111– co-marketing of Cellenion’s cellenONE with timsTOF SCP mass spectrometers 2021-11-15
Thermo Fisher–Bico: MS-based single cell proteomics, 202111– co-marketing Cellenion’s cellenONE + proteoCHIP with Orbitrap MS systems + TMT technology 2021-11-15
Nuritas–ECBF: investment, 202111 financing round Series B totalling $45m incl $7m from ECBF 2021-11-11
Nuritas–SEVERAL: investment, 202111 financing round Series B $45m led by Cleveland Avenue + incl ECBF 2021-11-11
Life Sciences Partners–EQT: investment, 202111–202202 acquisition €450m upfront with €112.5m in cash + €337.5m in shares plus €25m milestones 2021-11-10
Nebula Biocides–High-Tech Gründerfonds: investment, 202111 seed financing round totalling €1.6m incl investor HTGF 2021-11-10
Nebula Biocides–Mecklenburg-Vorpommern (govt): investment, 202111 seed financing round totalling €1.6m incl investor MBMV 2021-11-10
Nebula Biocides–OTHER: investment, 202111 seed financing round totalling €1.6m incl strategic investor operating in cleaning + disinfection equipment 2021-11-10
Nebula Biocides–SEVERAL: investment, 202111 seed financing round €1.6m from HTGF + MBMV + undisclosed strategic investor 2021-11-10
Develco Pharma–SHS Capital: investment, 202111 existent portfolio company of SHS 2021-11-09
PathoQuest–SEVERAL: investment, 202111 financing round Series B up to €15m led by new investor SHS Capital 2021-11-09
PathoQuest–SHS Capital: investment, 202111 financing round Series B totalling up to €15m incl new + lead investor SHS Capital 2021-11-09
PathoQuest–Verve Capital Partners: investment, 202111 financing round Series B totalling up to €15m incl existing + co-investor Verve Ventures 2021-11-09
PhagoMed–BioNTech: investment, 202111 acquisition estimated €150m of PhagoMed by BioNTech 2021-11-09
Phenox–SHS Capital: investment, 202111 existent portfolio company of SHS 2021-11-09
GlycoEra–5AM Ventures: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor 5AM Ventures 2021-11-05
GlycoEra–LimmaTech Biologics: investment, 202111 financing round Series A totalling CHF45m incl co-investor LimmaTech Biologics 2021-11-05
GlycoEra–Roche: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Roche Venture Fund 2021-11-05
GlycoEra–SEVERAL: investment, 202111 financing round Series A CHF45m co-led by 5AM Ventures + RVF + Sofinnova Partners 2021-11-05
GlycoEra–Sofinnova: investment, 202111 financing round Series A totalling CHF45m incl co-lead investor Sofinnova Partners 2021-11-05
GlycoEra–Trophic Communications: public relations, 202111 service existent by Trophic Communications 2021-11-05
Life Sciences Partners–SEVERAL: investment, –202111–202202 final closing of LSP 7 fund at hard cap of €1b 2021-11-04
Mainz Biomed–SEVERAL: investment, 202111 IPO $10m with 2m common shares at $5/share at Nasdaq Capital Market 2021-11-04
Roche–Novartis: investment, 202111 repurchase of total equity stake held by Novartis for CHF19b by Roche 2021-11-04
Insilico Biotechnology–Yokogawa: investment, 202111 acquisition 100% of Insilico Biotechnology AG by Yokogawa Electric Corp 2021-11-02
Capstan Therapeutics–SEVERAL: investment, 202111 seed financing round $63m led by NVF + OrbiMed 2021-11-01
Sanming Minhe Pharmaceutical Technology–Enzymaster: investment, 202111 acquisition of Sanming Minhe by Enzymaster 2021-11-01
Pan Cancer T–Akampion: public relations, 202111 service existent by Akampion 2021-10-28
Immunai–SEVERAL: investment, 202110 financing round Series B $215m led by Koch Disruptive Technologies 2021-10-27
Noxxon–LifeSci: public relations, 202110 service existent LifeSci Advisors is investor/media relations contact 2021-10-27
Ajinomoto–Insilico Biotechnology: biopharma production technology, 202110– collab using digital twins to develop cell culture processes w Genexine 2021-10-26
DNA Script–Merck (DE): investment, 202110 financing round Series C totalling $165m incl existing + co-investor M Ventures 2021-10-26
DNA Script–SEVERAL: investment, 202110 financing round Series C $165m co-led by Coatue Management + Catalio Capital Management 2021-10-26
Exciva–Andera Partners: investment, 202110 financing round Series A totalling €9m incl lead investor Andera Partners 2021-10-26
Exciva–Cure8: investment, 202110 financing round Series A totalling €9m incl co-investor Cure8 2021-10-26
Exciva–LBBW: investment, 202110 financing round Series A totalling €9m incl co-investor LBBW Venture Capital 2021-10-26
Exciva–SEVERAL: investment, 202110 financing round Series A €9m led by Andera Partners 2021-10-26
Valneva–SEVERAL: investment, 202110 private placement €76m of ordinary shares) at €17/share outside of US 2021-10-26
Valneva–SEVERAL: investment, 202110 public offering $653k+$13.3m of ADSs (each 2 ordinary shares) at $39.42/ADS in US 2021-10-26
Ariceum Therapeutics–Ipsen: investment, 202010 Ipsen became shareholder by selling rights to satoreotide to Ariceum (then SatoSea Oncology GmbH) 2021-10-22
Ariceum Therapeutics–Ipsen: satoreotide, 202010 acquisition of all rights from Ipsen which became shareholder of Ariceum (then SatoSea Oncology GmbH) 2021-10-22
Emergence Therapeutics–Mablink Bioscience: ADC technology, 202110– license for use of PSARlink drug-linker to develop ADC targeting Nectin-4 2021-10-21
Leucid Bio–2Invest: investment, 202110 financing round Series A totalling £11.5m incl new + co-investor 2InvestAG 2021-10-21
Leucid Bio–SEVERAL: investment, 202110 financing round Series A £11.5m led by Epidarex + Vulpes Investment Management 2021-10-21
InflaRx–Germany (govt): grant, 202110– grant up to €43.7m from BMBF + BMG for developm of vilobelimab for Covid-19 2021-10-19
Roche–Ibex.ai: digital pathology, 202110– collab integration of Galen AI-based cancer dx platform into Roche’s Navify Digital Pathology 2021-10-18
Abalos Therapeutics–SEVERAL: investment, 202110 financing round Series A extension €32.5m led by Seventure Partners 2021-10-14
Computomics–Amathaon Capital: investment, 202110 acquisition €na of minority stake by Amathaon Capital 2021-10-14
Computomics–Baden-Württemberg (govt): investment, 202110 existent seed investor MBG Mittelständische Beteiligungsgesellschaft Baden-Württemberg 2021-10-14
Computomics–BASF: investment, 202110 acquisition €na of minority stake by BASF Venture Capital GmbH 2021-10-14
UbiSim–Labster: investment, 202110– acquisition of UbiSim by Labster SIGNED 2021-10-14
VeroVaccines–SEVERAL: investment, 202110 financing round Series B mid-7-figure € from consortium of investors from Germany + Switzerland 2021-10-14
Creapaper–eCapital: investment, 202110 financing round Series B totalling €20m incl existing investor eCapital 2021-10-06
Creapaper–EU (govt): investment, 202110 financing round Series B totalling €20m incl new investor EIC Fund 2021-10-06
Creapaper–JS Capital: investment, 202110 financing round Series B totalling €20m incl new investor JS Capital 2021-10-06
Creapaper–Ranpak: investment, 202110 financing round Series B totalling €20m incl new investor Ranpak 2021-10-06
Creapaper–Schusterman Family Investments: investment, 202110 financing round Series B totalling €20m incl new investor Schusterman Family Investments 2021-10-06
Creapaper–SEVERAL: investment, 202110 financing round Series B €20m 2021-10-06
Creapaper–Soros Capital: investment, 202110 financing round Series B totalling €20m incl new investor Soros Capital 2021-10-06
Atbtherapeutics–Trophic Communications: public relations, 202110 service existent by Trophic Communications 2021-10-05
Cellecta–Merck (DE): CRISPR technology, 202110– license for CRISPR-Cas9 technology to Cellecta 2021-10-05
Exo Therapeutics–SEVERAL: investment, 202120 financing round Series B $78m lead by new investor Nextech invest 2021-10-05
iOmx Therapeutics–SEVERAL: investment, 202110 financing round Series B €65m co-led by Athos Service GmbH + MIG Capital AG 2021-10-05
Pierre Fabre–Atara Biotherapeutics: tabelecleucel, 202110– collab $45m upfront + $320m milestones + royalties excl sales in EMEA for EBV+ cancers 2021-10-04
QInstruments–Bico: investment, 202110 acquisition 100% cash/debt free for €58.25m upfront + €3m milestones thereof 13% paid in new Bico shares 2021-10-01
Isarna Therapeutics–Trophic Communications: public relations, 202109 service existent by Trophic Communications 2021-09-30
Applied Microarrays–Schott: investment, 202109–202110 acquisition of AMI by Schott Minifab 2021-09-28
Hadean Ventures–SEVERAL: investment, 202109 first closing of Hadean Capital I fund at €90m 2021-09-27
Thermo Fisher–Carbon Engineering: analytical technology, 202109 collab existent direct air capture technology to reduce CO2 emissions 2021-09-23
Univ Aarhus–Novo Group: grant, 202109–202808 grant DKK630m (€84.7m) to establish NNF CO2 Research Center at AU + six satellite institutes 2021-09-22
Arctos Medical–Novartis: investment, 202109 acquisition by Novartis 2021-09-21
Biotest–Grifols: investment, 202109–202204 public cash tender offer €895m for remaining 54.5% of shares at €34/ordinary share + €37/preferred share 2021-09-17
Creat (CN)–Grifols: investment, 202109 acquisition 100% of Tiancheng Germany owning 90% voting rights + 45% total capital of Biotest for €773m cash 2021-09-17
next pagenext page 1 2 3 ... 5 6 7 ... 48 49 50  next pagenext page



Advertisement

Picture [iito] Männer Ballett 650x100px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture EBD Group Biotech Showcase 2023 San Francisco 650x300px

» top